98%
921
2 minutes
20
Background: Peanut allergy affects 1% to 2% of European children. Early introduction of peanut into the diet reduces allergy in high-risk infants.
Objective: We aimed to determine the optimal target populations and timing of introduction of peanut products to prevent peanut allergy in the general population.
Methods: Data from the Enquiring About Tolerance (EAT; n = 1303; normal risk; 3-year follow-up; ISRCTN14254740) and Learning Early About Peanut Allergy study (LEAP; n = 640; high risk; 5-year follow-up; NCT00329784) randomized controlled trials plus the Peanut Allergy Sensitization (PAS; n = 194; low and very high risk; 5-year follow-up) observational study were used to model the intervention in a general population. Peanut allergy was defined by blinded peanut challenge or diagnostic skin prick test result.
Results: Targeting only the highest-risk infants with severe eczema reduced the population disease burden by only 4.6%. Greatest reductions in peanut allergy were seen when the intervention was targeted only to the larger but lower-risk groups. A 77% reduction in peanut allergy was estimated when peanut was introduced to the diet of all infants, at 4 months with eczema, and at 6 months without eczema. The estimated reduction in peanut allergy diminished with every month of delayed introduction. If introduction was delayed to 12 months, peanut allergy was only reduced by 33%.
Conclusions: The preventive benefit of early introduction of peanut products into the diet decreases as age at introduction increases. In countries where peanut allergy is a public health concern, health care professionals should help parents introduce peanut products into their infants' diet at 4 to 6 months of life.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689252 | PMC |
http://dx.doi.org/10.1016/j.jaci.2022.09.042 | DOI Listing |
Int Arch Allergy Immunol
September 2025
Background: Tree nut/Peanut (TN/PN) allergies are among the most common pediatric food allergies, often persisting into later life and posing significant clinical risks. The likelihood of tolerance acquisition varies, and predictive factors remain inadequately defined in clinical practice.
Objective: To evaluate the clinical and laboratory features associated with anaphylaxis risk and tolerance development in pediatric patients with TN/PN allergy, and to determine the role of aeroallergen sensitization, comorbid atopic diseases, and skin test reactivity.
Allergy
September 2025
Allergy Immunology, Murdoch Children's Research Institute, Parkville, Australia.
Background: Uncertainty exists regarding the health-related quality of life (HRQL) benefits of food allergen oral immunotherapy (OIT). Up-to-date meta-analyses incorporating HRQL data from recent randomised trials are lacking.
Methods: Systematic searches of MEDLINE, Embase, CENTRAL and Google Scholar were conducted for food OIT randomised trials (versus any comparator) that measured HRQL with a validated instrument (27 July 2023).
Allergy
September 2025
Global Research Organization, Beckman Coulter Life Sciences, Marseille, France.
Ann Allergy Asthma Immunol
September 2025
Department of Pediatrics, Division of General Pediatrics, The University of Tennessee Health Science Center and LeBonheur Children's Hospital, Memphis, Tennessee; Department of Pediatrics, Division of Allergy and Pulmonology, The University of Tennessee Health Science Center and LeBonheur Children's
Eur Ann Allergy Clin Immunol
September 2025
Department of Clinical Immunology, AUSL Bologna, Bologna, Italy.